Gurnit Atwal

Gurnit Atwal

Auto-generated profile, based on publicly available information

Gurnit Atwal

Computational Biology Program, Ontario Institute for Cancer Research, Toronto, Ontario, Canada

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2020 in Nature
Verified
Journal Article
Open access
PDF file
Taobo HuTaobo Hu
Taobo Hu
LALauri A. Aaltonen
Lauri A. Aaltonen
FAFederico Abascal
Federico Abascal
AAAdam Abeshouse
Adam Abeshouse
HAHiroyuki Aburatani
Hiroyuki Aburatani
CMChristian von Mering
Christian von Mering
Cancer is driven by genetic change, and the advent of massively parallel sequencing has enabled systematic documentation of this variation at the whole-genome scale1–3. Here we report the integrative analysis of 2,658 whole-cancer genomes and their matching normal tissues across 38 tumour types from the Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium of the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA). We describe the generation of the PCAWG resource, facilitated by international data sharing using compute clouds. On average, cancer genomes contained 4–5 driver mutations when combining coding and non-coding genomic elements; however, in around 5% of cases no drivers were identified, suggesting that cancer driver discovery is not yet complete. Chromothripsis, in which many clustered structural variants arise in a single catastrophic event, is frequently an early event in tumour evolution; in acral melanoma, for example, these events precede most somatic point mutations and affect several cancer-associated genes simultaneously. Cancers with abnormal telomere maintenance often originate from tissues with low replicative activity and show several mechanisms of preventing telomere attrition to critical levels. Common and rare germline variants affect patterns of somatic mutation, including point mutations, structural variants and somatic retrotransposition. A collection of papers from the PCAWG Consortium describes non-coding mutations that drive cancer beyond those in the TERT promoter4; identifies new signatures of mutational processes that cause base substitutions, small insertions and deletions and structural variation5,6; analyses timings and patterns of tumour evolution7; describes the diverse transcriptional consequences of somatic mutation on splicing, expression levels, fusion genes and promoter activity8,9; and evaluates a range of more-specialized features of cancer genomes8,10–18.

5 February 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
WJWei Jiao
Wei Jiao
GAGurnit Atwal
Gurnit Atwal
PPPaz Polak
Paz Polak
RKRosa Karlić
Rosa Karlić
ECEdwin Cuppen
Edwin Cuppen
LSLincoln D. Stein
Lincoln D. Stein
In cancer, the primary tumour’s organ of origin and histopathology are the strongest determinants of its clinical behaviour, but in 3% of cases a patient presents with a metastatic tumour and no obvious primary. Here,as part of the ICGC/TCGA Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium, we train a deep learning classifier to predict cancer type based on patterns of somatic passenger mutations detected in whole genome sequencing (WGS) of 2606 tumours representing 24 common cancer types produced by the PCAWG Consortium. Our classifier achieves an accuracy of 91% on held-out tumor samples and 88% and 83% respectively on independent primary and metastatic samples, roughly double the accuracy of trained pathologists when presented with a metastatic tumour without knowledge of the primary. Surprisingly, adding information on driver mutations reduced accuracy. Our results have clinical applicability, underscore how patterns of somatic passenger mutations encode the state of the cell of origin, and can inform future strategies to detect the source of circulating tumour DNA.

1 August 2017 in Cell Stem Cell
Verified
Journal Article
Closed access
NPNicole I. Park
Nicole I. Park
PGPaul Guilhamon
Paul Guilhamon
KDKinjal Desai
Kinjal Desai
RMRochelle F. McAdam
Rochelle F. McAdam
ELEllen Langille
Ellen Langille
PDPeter B. Dirks
Peter B. Dirks

1 September 2017 in Cell Stem Cell
Verified
Journal Article
Closed access
NPNicole I. Park
Nicole I. Park
PGPaul Guilhamon
Paul Guilhamon
KDKinjal Desai
Kinjal Desai
RMRochelle F. McAdam
Rochelle F. McAdam
ELEllen Langille
Ellen Langille
PDPeter B. Dirks
Peter B. Dirks

27 February 2024 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
MDMadison Darmofal
Madison Darmofal
SSShalabh Suman
Shalabh Suman
GAGurnit Atwal
Gurnit Atwal
MTMichael Toomey
Michael Toomey
JCJie-Fu Chen
Jie-Fu Chen
QMQuaid Morris
Quaid Morris
Tumor type guides clinical treatment decisions in cancer, but histology-based diagnosis remains challenging. Genomic alterations are highly diagnostic of tumor type, and tumor-type classifiers trained on genomic features have been explored, but the most accurate methods are not clinically feasible, relying on features derived from whole-genome sequencing (WGS), or predicting across limited cancer types. We use genomic features from a data set of 39,787 solid tumors sequenced using a clinically targeted cancer gene panel to develop Genome-Derived-Diagnosis Ensemble (GDD-ENS): a hyperparameter ensemble for classifying tumor type using deep neural networks. GDD-ENS achieves 93% accuracy for high-confidence predictions across 38 cancer types, rivaling the performance of WGS-based methods. GDD-ENS can also guide diagnoses of rare type and cancers of unknown primary and incorporate patient-specific clinical information for improved predictions. Overall, integrating GDD-ENS into prospective clinical sequencing workflows could provide clinically relevant tumor-type predictions to guide treatment decisions in real time. Significance: We describe a highly accurate tumor-type prediction model, designed specifically for clinical implementation. Our model relies only on widely used cancer gene panel sequencing data, predicts across 38 distinct cancer types, and supports integration of patient-specific nongenomic information for enhanced decision support in challenging diagnostic situations. See related commentary by Garg, p. 906. This article is featured in Selected Articles from This Issue, p. 897

8 December 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
WJWei Jiao
Wei Jiao
GAGurnit Atwal
Gurnit Atwal
PPPaz Polak
Paz Polak
RKRosa Karlić
Rosa Karlić
ECEdwin Cuppen
Edwin Cuppen
LSLincoln D. Stein
Lincoln D. Stein